Job Description

The University of Wisconsin-Madison, or UW-Madison for short, was founded in 1848 and is located in Madison, the capital of Wisconsin, USA. It is a world-leading public research university and ranked in the world of 2020. The university is ranked 32nd in the academic rankings and 41st in the 2020 US News World University Rankings. The University of Wisconsin-Madison is a founding member of the American Association of Universities and the Big Ten (Big Ten). It is known as a public Ivy League university, and its School of Pharmacy ranks seventh in the United States (US news 2020). Dr. Ting Fu's lab of the School of Pharmacy recruits post-doctors, doctoral students, joint doctoral students, and several visiting scholars. Madison, the capital of Wisconsin, has a beautiful environment and good public security. It has been rated as one of the ten most livable cities in the United States.

1．Laboratory and PI introduction: Dr. Ting Fu conducted her Ph.D research in Prof. Jongsook Kim Kemper's laboratory at the University of Illinois at Urbana-Champaign (UIUC) and obtained her Ph.D., and then continued her Postdoctoral research at the Salk Institute The laboratory of Prof. Ronald Evans, internationally renowned experts of nuclear receptors. The research directions of her doctoral and postdoctoral researches are all well centered on bile acid and its nuclear receptor FXR. During the doctoral period, the research focused on obesity, diabetes, fatty liver diseases, and other metabolic diseases; the postdoctoral period mainly focused on colon cancer, inflammatory bowel diseases, novel Bile acids, and gut microbes. During Ph.D and postdoc time, she published many first-author research articles in Nature, Cell, PNAS, MCB, and other journals, and also co-published many articles on Nature, Cell Metabolism, Aging cell, Cancer Cell, etc.

2. Research direction: In recent 5 years, Fu lab will continue to study intestinal physiology and metabolism, inflammation and cancer, and gut microbiome around nuclear receptors FXR and its natural ligand bile acids. Our goal is to discover some natural bile acids as diagnostic biomarkers and develop some bile acids related smallmolecule compounds as therapeutic tools targeting cancel metabolism and immunomodulation. In addition, the laboratory will use pharmacological tools, gene knockout mice (genetic tools), human and mouse 3D small intestinal cells (organoids), mucosal immunology, host and microbiome sequencing, and a series of platforms and technologies to study intestinal diseases. More information about the PI and the lab: https://apps.pharmacy.wisc.edu/sopdir/ting_fu/index.php https://www.linkedin.com/in/shirley-ting-fu-82390473/

3. Application requirements:
Postdoctoral researcher position: encourage scholars with Ph.D degree of relevant backgrounds in molecular biology, cell biology, immunology, human and animal physiology, nutrition, microbiology, etc. to apply. Those with certain research experience will be preferred. Have good English reading, writing and communication skills, critical thinking ability, responsible and having good working ethic, ambitious and determined, teamwork and collaborative spirit.

4. Contact: Welcome to consult and apply. Please send relevant application materials to [email protected] Please merge the Cover Letter and CV into one PDF file and send it to Dr. Fu's mailbox. Please indicate postdoc or Ph.D application in the title. Please briefly describe your future career development plan in the Cover Letter.

5. Salary: The postdoctoral and doctoral students who are hired will enjoy the uniform salaries and benefits of the University of Wisconsin-Madison and various research and learning resources.

Selected publication:
1. Ting Fu, Sally Coulter, Eiji Yoshihara, Tae Gyu Oh, Sungsoon Fang, Fritz Cayabyab, Qiyun Zhu, Michael Downes*, Ronald M. Evans*, et al. FXR regulates intestinal stem cell proliferation. VOLUME 176, ISSUE 5, P1098-1112.E18, FEBRUARY 21, 2019, Cell.
2. Sunmi Seok*, Ting Fu*, Sung-E Choi, Yang Li, Rong Zhu, Subodh Kumar, Xiaoxiao Sun, Gyesoon Yoon, Yup Kang, Wenxuan Zhong, Jian Ma, Byron Kemper, and Jongsook Kim Kemper. Transcriptional regulation of autophagy by an FXR/CREB1 axis. Nature, 516, 108–111, 2014. * equal contribution
3. Ting Fu, SungE Choi, Dong-Hyun Kim, Sunmi Seok, Kelly Suino-Powell, H. Eric Xu, and Jongsook Kim Kemper. Aberrantly elevated miR-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor β-Klotho. PNAS, 2012 Oct 2; 109(40):16137-42.
4. Ting Fu, Sunmi Seok, Sung-E Choi, Zhang Huang, Kelly Suino-Powell, H. Eric Xu, Byron Kemper, and Jongsook Kim Kemper. MiR-34a inhibits beige and brown fat formation in obesity in part by suppressing adipocyte FGF21 signaling and SIRT1 function. Molecular and Cellular Biology, 2014, Nov 15; 34(22):4130-42.
5. Ting Fu, Youngchea Kim, Dong-Hyun Kim, Sunmi Seok, Kelly Suino-Powell, H. Eric Xu, Byron Kemper, and Jongsook Kim Kemper. FXR primes the liver for intestinal FGF15 signaling by transient induction of βklotho. Molecular Endocrinology, 2015 Oct 23; doi: http://dx.doi.org/10.1210/me.2015-1226
6. SungE Choi, Ting Fu, Sunmi Seok, Dong-Hyun Kim, Eunkyung Yu, Kwan-woo Lee, Yup Kang, Xiaoling Li, Byron Kemper, Jongsook Kim Kemper. Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell. 2013 Dec; 12(6):1062-72.
7. Robert A. Quinn, Alexey V. Melnik, Alison Vrbanac, Ting Fu, …Ronald M. Evans, Victor Nizet, Rob Knight, and Pieter C. Dorrestein, et al. Global Chemical Impacts of the Microbiome Include Unique Bile Acid Conjugates that Stimulate FXR. Nature, 2020 Mar; 579(7797):123-129.
8. Tae Gyu Oh, Susy Kim, Cyrielle Caussy, Ting Fu,…Michael R. Downes, Ronald M. Evans,* and Rohit Loomba,*et al. A Universal Gut Microbiome-Derived Signature for Predicting NAFLD-Cirrhosis Externally Validated with Geographically Independent Cohorts. Cell Metabolism.
https://scholar.google.com/citations?user=Xgj_zLsAAAAJ&hl=en